- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05196529
Inspiratory Muscle Training in ME/CFS and COVID-19 Survivors (Inspire ME)
Inspiratory Muscle Training in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and COVID-19 Survivors
Coronavirus-2019 (COVID-19) is a viral disease leading to respiratory dysfunction, but it may also affect the brain and result in the development of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This may be the result of the COVID-19 virus infecting regions of the brain responsible for respiratory control. The symptoms of COVID-19 long haulers and ME/CFS may be lessened via an 8-week inspiratory muscle training protocol which is a simple and easy training protocol which can be done at a patient's home.
Thus, this project will investigate changes in the breathing and cardiovascular responses to stimuli in three groups of participants: 1) healthy control individuals; 2) patients diagnosed with ME/CFS (mild to moderate symptoms); and 3) individuals with previous COVID-19 infection with long-haul symptoms lasting for at least 3 months. Participants will 1) breathe hypoxic gas (10% O2) for 5 minutes; 2) breath hypercapnic gas (5% CO2) for 5 minutes; 3) breathe at a rate of 6 breaths per minute for a total of 8 breaths (paced deep breathing); and 4) complete 10 minutes upright tilt (70 degrees head up on a tilt-table). Patients will also complete 2 questionnaires concerning their symptoms and a 15 minute cognitive function test on a lab laptop. This will allow for the assessment of the brain's control over blood pressure and breathing. Participants will also complete a 6-minute walking exercise test at their own speed as a measure of their aerobic fitness. We hypothesize that COVID-19 survivors will have a worse cardiovascular and autonomic response and lower fitness, similar to ME/CFS patients, compared to healthy participants.Further, this will be improved after 8-weeks of inspiratory muscle training. These results may help clinicians recognize ME/CFS symptoms in patients recovering from COVID-19.
Study Overview
Status
Intervention / Treatment
Detailed Description
Approximately 10 women and 10 men between the ages of 18-65 will be tested in each of 3 groups:
- Control participants will be free of previously diagnosed cardiovascular, metabolic, autonomic, or respiratory disease.
- COVID-19 participants will have both an official diagnosis and an official clearance of COVID-19. Patients will have long-haul symptoms for at least 3 months. Patients will be recruited via media, social media and clinical collaborators.
- ME/CFS participants will be recruited via media, social media and clinical collaborators. Only those with mild to moderate symptoms who can complete a 6 minute walk test will be recruited.
Prospective participants will be patients of the University Health Network (UHN) or Women's College Hospital, community members, friends, family, and co-workers of laboratory staff and students. Patients will be recruited from clinical sites by poster recruitment at collaborative clinics.
Exclusion criteria are severe symptoms of chronic fatigue syndrome, inability to stand on a tilt table, inability to walk for 6 minutes, previous cardiorespiratory disease (except for COVID-19 long-hauler symptoms and chronic fatigue syndrome itself), and inability to understand and read English.
Participants will be recruited via established clinical collaborators, from York University's student and staff population, previously known relationships with the research staff, poster recruitment, and advertisements on social media sites (e.g. York U reddit, Facebook, Instagram, LinkedIn and Twitter). Social media will not be used for conversations, only for advertisement purposes. Postings will include only the information that is included on the print poster. Recruitment at clinics will be done via posters.
Participants will fill out clinical questionnaires (COMPASS31 and DePaul Symptom Questionnaire) and complete a cognitive function test using BrDI software developed by Dr. Lauren Sergio. This software program is located on a lab laptop and consists of trials whereby participants move a mouse on a screen in particular directions as instructed. They will then complete the following in random order: 1) breathe hypoxic gas (10% O2) for 5 minutes; 2) breathe hypercapnic gas (5% CO2) for 5 minutes; 3) breathe at a rate of 6 breaths per minute (paced deep breathing); and 4) 10 minutes upright tilt (70 degrees on a tilt-table). Each trial will be separated by 10 minutes of supine rest. Participants will also complete a voluntary walking test whereby the distance walked in 6 minutes will be measured as an index of aerobic fitness. All of these trials will be conducted in 336 Calumet College and will be conducted both before and after the 8-weeks of inspiratory muscle training described below (i.e. at both their first and second visits).
All participants will be equipped to measure heart rate, beat-to-beat blood pressure, brain blood flow, ventilation and end-tidal gases. Heart rate (HR) will be measured by electrocardiogram (ECG), and blood pressure will be monitored using a beat-by-beat non-invasive blood pressure device on the middle finger (NexFin). Brain blood flow velocity from the middle cerebral artery in the brain will be recorded using ultrasound and a 2MHz probe (Multigon Industries Inc.) positioned on the temple and held in place by an adjustable head-band. Respiratory outcomes such as ventilation, tidal volume, breathing frequency, exhaled gases will be measured through a mouthpiece that will be attached to a pneumotachometer (a nose plug will be worn).
These experiments will take approximately 2.5 hours per testing session.
Using commercially available devices, the 8-week inspiratory muscle training protocol consists of using 80% of maximal inspiratory pressure (determined in lab), 3x per week, 6 sets of 6 repetitions. Each set will be separated by decreasing lengths of time over the 8 weeks starting at a 30 second interim. This totals 36 inhalations 3 times per week. Progress will be determined via weekly phone calls with the participants and progress will also be logged by participants over the 8 weeks
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Heather Edgell, PhD
- Phone Number: 22927 14167362100
- Email: edgell@yorku.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M3J1P3
- York University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Control participants will be free of previously diagnosed cardiovascular, metabolic, autonomic, or respiratory disease.
- COVID-19 participants will have both an official diagnosis and an official clearance of COVID-19. Patients will have long-haul symptoms for at least 3 months. Patients will be recruited via media, social media and clinical collaborators.
- ME/CFS participants will be recruited via media, social media and clinical collaborators. Only those with mild to moderate symptoms who can complete a 6 minute walk test will be recruited.
Exclusion Criteria:
- severe symptoms of chronic fatigue syndrome
- inability to stand on a tilt table
- inability to walk for 6 minutes
- previous cardiorespiratory disease (except for COVID long-hauler symptoms and chronic fatigue syndrome itself)
- inability to understand and read English.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inspiratory muscle training
The 8-week inspiratory muscle training protocol consists of using 80% of maximal inspiratory pressure (determined in lab), 3x per week, 6 sets of 6 repetitions.
Each set will be separated by decreasing lengths of time over the 8 weeks starting at a 30 second interim.
This totals 36 inhalations 3 times per week.
Progress will be determined via weekly phone calls with the participants and progress will also be logged by participants over the 8 weeks.
|
All participants will undergo inspiratory muscle training.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chemoreflex function
Time Frame: 8 weeks
|
Ventilatory responses to the administration of 10% hypoxia or 5% hypercapnia will be measured.
|
8 weeks
|
Clinical autonomic function
Time Frame: 8 weeks
|
Cardiovascular responses to autonomic battery of tests
|
8 weeks
|
Vascular function
Time Frame: 8 weeks
|
Brachial artery dilation response to 5 minutes of circulatory occlusion (flow-mediated dilation).
|
8 weeks
|
Cognitive function
Time Frame: 8 weeks
|
Performance on proprietary cognitive function software
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiorespiratory fitness
Time Frame: 8 weeks
|
6-minute walk distance
|
8 weeks
|
ME symptoms
Time Frame: 8 weeks
|
DePaul symptom questionnaire
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Heather Edgell, PhD, York University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Central Nervous System Diseases
- Nervous System Diseases
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Pain
- Neurologic Manifestations
- Disease
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Musculoskeletal Pain
- Central Nervous System Infections
- COVID-19
- Syndrome
- Myalgia
- Fatigue Syndrome, Chronic
- Encephalomyelitis
Other Study ID Numbers
- SOLVE ME/CFS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post-acute COVID-19 Syndrome
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Azienda Socio Sanitaria Territoriale di LeccoRecruitingPost Acute COVID-19 SyndromeItaly
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Massachusetts General HospitalRecruitingDysexecutive Syndrome | Post-Acute Sequelae of COVID-19United States
-
Adhera Health, Inc.Institut Català de la Salut; Andaluz Health ServiceCompletedFatigue | Post-Acute COVID19 SyndromeSpain
-
Leiden University Medical CenterUniversity Medical Center Groningen; UMC Utrecht; Academisch Medisch Centrum... and other collaboratorsRecruitingCOVID-19 | Post-Acute COVID19 Syndrome | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Post COVID-19 Condition | Multi-System Inflammatory Syndrome in Children | Pediatric Inflammatory Multisystem SyndromeNetherlands
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Timothy HenrichShionogi Inc.Enrolling by invitationLong COVID | Post-Acute COVID-19 | Post Acute Sequelae of COVID-19United States
Clinical Trials on Inspiratory muscle training
-
Elisabethinen HospitalUnknownStem Cell Transplantation | Inspiratory Muscle Training | Respiratory Muscle TrainingAustria
-
Universidad Complutense de MadridColegio Profesional de Fisioterapeutas de la Comunidad de Madrid, Madrid,...CompletedQuality of Life | Covid19 | Respiratory Muscle Training | Respiratory Function Test | Psychosocial FactorSpain
-
Dokuz Eylul UniversityDokuz Eylül University, Scientific Research Projects Coordination UnitCompleted
-
University of British ColumbiaNatural Sciences and Engineering Research Council, CanadaCompletedRespiratory Muscles | Breathing ExercisesCanada
-
King Saud UniversityCompleted
-
Universidade do PortoUnknownMuscle Weakness | Dyspnea | Reactive Airways Dysfunction Syndrome (Disorder)Portugal
-
Gazi UniversityCompletedAllogeneic Hematopoietic Stem Cell Transplantation
-
Gazi UniversityCompleted
-
Federal University of Health Science of Porto AlegreIrmandade Santa Casa de Misericórdia de Porto AlegreUnknownChronic Kidney Disease